A phase II trial of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) chemotherapy plus bevacizumab (bev) for patients (pts) with unresectable stage IV colon cancer and a synchronous asymptomatic primary tumor: Updated results of NSABP C-10 with definitive survival analysis.
Laurence E. McCahill
No relevant relationships to disclose
Greg Yothers
Consultant or Advisory Role - Genentech (U)
Saima Sharif
No relevant relationships to disclose
Nicholas J. Petrelli
No relevant relationships to disclose
Samia H. Lopa
No relevant relationships to disclose
Michael J. O'Connell
No relevant relationships to disclose
Norman Wolmark
Consultant or Advisory Role - Sanofi (U)